{"id":553353,"title":"Notice to Stakeholders - Policy Statement on the Naming of Biologic Drugs - Canada.ca","sourceCode":"hc","sourceName":"Health Canada","language":"en","captureDate":"2026-03-06","captureTimestamp":"2026-03-06T02:48:39.933000+00:00","jobId":6,"originalUrl":"https://www.canada.ca/en/health-canada/services/drugs-health-products/biologics-radiopharmaceuticals-genetic-therapies/biosimilar-biologic-notice-to-stakeholders-drugs-naming-of-biologics.html","snippet":"Notice to Stakeholders - Policy Statement on the Naming of Biologic Drugs Health Canada thanks those who responded to the 2018 Consultation on the Naming of Biologic Drugs. A “ What We Heard ” Report summarizing the results of this consultation has been published on the Health…","rawSnapshotUrl":"/api/snapshots/raw/553353","browseUrl":"https://replay.healtharchive.ca/job-6/20260306024839/https://www.canada.ca/en/health-canada/services/drugs-health-products/biologics-radiopharmaceuticals-genetic-therapies/biosimilar-biologic-notice-to-stakeholders-drugs-naming-of-biologics.html#ha_snapshot=553353","mimeType":"text/html","statusCode":200,"captureBackend":"browsertrix","captureFidelity":"high"}